Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer:a Single-arm, Phase II Exploratory Clinical Study
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Adebrelimab (Primary) ; Dalpiciclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 30 Nov 2023 New trial record